abstract: BACKGROUND: Approximately 30% of @entity1 undergoing @entity358 ( @entity358 ) for @entity955 ( @entity955 ) have clinical recurrence of @entity955 , and a great majority of these @entity1 have recovery of vein conduction. @entity859 can be associated with acute recovery of conduction to the pulmonary veins immediately after isolation. However, it is not known whether this is prognostic for permanent recovery of conduction or recurrence of @entity955 . METHODS: @entity1 with paroxysmal @entity955 underwent @entity358 , with administration of @entity859 after electrical isolation. Those with transient conduction recovery (TCR+) underwent no further ablation and were compared to those without (TCR-) for clinical @entity955 recurrence and conduction recovery at second procedure. RESULTS: Seventy-two consecutive @entity358 @entity1 were studied (mean age 56.7    9.2, 61 male). Twenty-five (35%) @entity1 had transient recovery of conduction with @entity859 . After 1 year, 18 @entity1 (25%) had symptomatic recurrence of @entity955 . In this group of 18 @entity1 , 6 were TCR+ at initial ablation (sensitivity 33%, NPV = 74%). In the remaining group of 54 @entity1 free from @entity955 recurrence, 35 @entity1 (65%) were TCR- at initial ablation (specificity 65%, @entity2286 = 24%). All 18 @entity1 with recurrent @entity955 underwent repeat procedure and had at least 1 pulmonary vein with recurrent conduction. The initial @entity859 test correctly predicted 13 out of 36 (36%) veins, with positive predictive value 90% and negative predictive value 15%. CONCLUSIONS: @entity859 testing for TCR does not appear to predict recurrence of clinical @entity955 . TCR- veins remain susceptible to conduction recovery, as determined at the follow-up procedure.

title: Does XXXX response predict clinical recurrence of @entity955 after @entity358 ?

answer: @entity859 :: (MESH:D000241,Chemical) :: ['adenosine']


abstract: INTRODUCTION AND OBJECTIVE: Tinea @entity3100 are due to @entity364 by dermatophytes. They are common in developing countries including Morocco. The objective of this study intended to describe the epidemiology, clinical and mycological profile of @entity3100 in Avicenna military hospital of Marrakech. @entity1 AND METHODS: This is a retrospective study over an 8-year period (from 1st January 2006  to 31st December 2013). All @entity1 targeted through this study presented to the laboratory with the suspicion of @entity3100 , they were under a detailed investigation with a careful mycological analysis; diagnosis of @entity3100 was established as the direct examination and/or the sampling proved positive. RESULTS: Of the 334  @entity1 investigated, 216  had a TC with an overall prevalence of 64.67%. The average age was 6  years. The M/F sex ratio was 0.55. The isolated dermatophytes were @entity14476 with 105  cases (63.26%), @entity12735 violaceum in 44  cases (26.51%), T.  mentographytes in 8  cases (4.81%), M.  langeronii in 5  cases (3.01%), @entity12735 in 3  cases (1.8%) and T.  schoenleinii in 1  case (0.61%). The contact with animals was found in 40% of cases and immunosupression in 3.47% of cases. We verify through our investigation that tineas predominate among school age @entity1 with a female predominance. The epidemiological profile of TC in our study is similar to that of other studies in Moroccan and Maghrebian countries investigations. CONCLUSION: The TC is relatively a mild @entity281 but can be confused with other dermatoses not easy to diagnose. For this reason, their treatment necessitates a mycological analysis.

title: [Tinea XXXX in the military hospital Avicenna (Morocco): Review of 8years (2006-2013)].

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'PATIENTS']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity364 :: ('MESH:D009181', 'Disease') :: ['fungal infection']

entities_list: @entity3100 :: ('MESH:D014006', 'Disease') :: ['capitis', 'tinea capitis']

entities_list: @entity14476 :: ('63405', 'Species') :: ['Microsporum canis']

entities_list: @entity12735 :: ('63417', 'Species') :: ['Trichophyton', 'T.  verrucosum']

answer: @entity3100 :: (MESH:D014006,Disease) :: ['capitis']


abstract: WHAT IS KNOWN AND OBJECTIVE: Regular blood transfusions in the management of @entity2590 ( @entity2590 ) often lead to @entity68 overload. The main objective of this study was to evaluate the impact of medication adherence on the effectiveness of @entity27101 for the treatment of transfusional @entity68 overload in @entity1 with @entity2590 . Secondary objectives were to describe treatment effectiveness and safety in daily clinical practice. METHODS: A longitudinal, retrospective, observational study was carried out in a university hospital. The inclusion criteria were age over 18 years, @entity2590 diagnosis and treatment with @entity27101 for transfusion-dependent @entity68 overload during the period of study (from January 2011 to April 2015). Treatment effectiveness was estimated by serum ferritin (SF), and adherence was measured by medication possession ratio (MPR). Clinically relevant analytical alterations during the treatment and reasons for treatment discontinuation were also assessed. RESULTS: Thirty-five @entity1 were included in the study. Median SF at baseline was 1636  g/L, and it decreased to 1399  g/L during follow-up. The median adherence rate was 92%, although only 54  8% of the @entity1 maintained @entity27101 adherence >= 90% during the whole duration of treatment. Adherence rate was inversely correlated to SF (r = -0  288, P = 0  004). The median ( @entity4667 , @entity2251 ) duration of treatment was 11 (3  0, 37  8) months. The most common reasons for treatment discontinuation were @entity8 (35%) and @entity1 's @entity204 (25%). WHAT IS NEW AND CONCLUSION: @entity27101 's effectiveness, measured by the decrease in SF, was significantly better in adherent @entity1 . The most frequent reason for treatment discontinuation was @entity8 . Developing strategies to improve @entity27101 treatment adherence and monitoring renal function in those @entity1 should be key points in pharmaceutical care.

title: Impact of medication adherence on the effectiveness of @entity27101 for the treatment of transfusional @entity68 overload in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal toxicity']

entities_list: @entity2590 :: ('MESH:D009190', 'Disease') :: ['myelodysplastic syndrome', 'MDS']

entities_list: @entity27101 :: ('MESH:C415250', 'Chemical') :: ['Deferasirox', 'deferasirox']

answer: @entity2590 :: (MESH:D009190,Disease) :: ['myelodysplastic syndrome']


abstract: WHAT IS KNOWN AND OBJECTIVE: Regular blood transfusions in the management of @entity2590 ( @entity2590 ) often lead to @entity68 overload. The main objective of this study was to evaluate the impact of medication adherence on the effectiveness of @entity27101 for the treatment of transfusional @entity68 overload in @entity1 with @entity2590 . Secondary objectives were to describe treatment effectiveness and safety in daily clinical practice. METHODS: A longitudinal, retrospective, observational study was carried out in a university hospital. The inclusion criteria were age over 18 years, @entity2590 diagnosis and treatment with @entity27101 for transfusion-dependent @entity68 overload during the period of study (from January 2011 to April 2015). Treatment effectiveness was estimated by serum ferritin (SF), and adherence was measured by medication possession ratio (MPR). Clinically relevant analytical alterations during the treatment and reasons for treatment discontinuation were also assessed. RESULTS: Thirty-five @entity1 were included in the study. Median SF at baseline was 1636  g/L, and it decreased to 1399  g/L during follow-up. The median adherence rate was 92%, although only 54  8% of the @entity1 maintained @entity27101 adherence >= 90% during the whole duration of treatment. Adherence rate was inversely correlated to SF (r = -0  288, P = 0  004). The median ( @entity4667 , @entity2251 ) duration of treatment was 11 (3  0, 37  8) months. The most common reasons for treatment discontinuation were @entity8 (35%) and @entity1 's @entity204 (25%). WHAT IS NEW AND CONCLUSION: @entity27101 's effectiveness, measured by the decrease in SF, was significantly better in adherent @entity1 . The most frequent reason for treatment discontinuation was @entity8 . Developing strategies to improve @entity27101 treatment adherence and monitoring renal function in those @entity1 should be key points in pharmaceutical care.

title: Impact of medication adherence on the effectiveness of XXXX for the treatment of transfusional @entity68 overload in @entity2590 .

answer: @entity27101 :: (MESH:C415250,Chemical) :: ['deferasirox']


abstract: WHAT IS KNOWN AND OBJECTIVE: Regular blood transfusions in the management of @entity2590 ( @entity2590 ) often lead to @entity68 overload. The main objective of this study was to evaluate the impact of medication adherence on the effectiveness of @entity27101 for the treatment of transfusional @entity68 overload in @entity1 with @entity2590 . Secondary objectives were to describe treatment effectiveness and safety in daily clinical practice. METHODS: A longitudinal, retrospective, observational study was carried out in a university hospital. The inclusion criteria were age over 18 years, @entity2590 diagnosis and treatment with @entity27101 for transfusion-dependent @entity68 overload during the period of study (from January 2011 to April 2015). Treatment effectiveness was estimated by serum ferritin (SF), and adherence was measured by medication possession ratio (MPR). Clinically relevant analytical alterations during the treatment and reasons for treatment discontinuation were also assessed. RESULTS: Thirty-five @entity1 were included in the study. Median SF at baseline was 1636  g/L, and it decreased to 1399  g/L during follow-up. The median adherence rate was 92%, although only 54  8% of the @entity1 maintained @entity27101 adherence >= 90% during the whole duration of treatment. Adherence rate was inversely correlated to SF (r = -0  288, P = 0  004). The median ( @entity4667 , @entity2251 ) duration of treatment was 11 (3  0, 37  8) months. The most common reasons for treatment discontinuation were @entity8 (35%) and @entity1 's @entity204 (25%). WHAT IS NEW AND CONCLUSION: @entity27101 's effectiveness, measured by the decrease in SF, was significantly better in adherent @entity1 . The most frequent reason for treatment discontinuation was @entity8 . Developing strategies to improve @entity27101 treatment adherence and monitoring renal function in those @entity1 should be key points in pharmaceutical care.

title: Impact of medication adherence on the effectiveness of @entity27101 for the treatment of transfusional XXXX overload in @entity2590 .

answer: @entity68 :: (MESH:D007501,Chemical) :: ['iron']


abstract: OBJECTIVE: To assess the effectiveness of inspiratory muscular training (IMT) on measures of strength, resistance, functional performance, and quality of life (QOL) for chronic @entity64 survivors. DESIGN: Double-blinded randomized controlled trial. SETTING: Research laboratory. @entity1 : Subjects (N=21) with @entity64 (11 @entity1 , 10 @entity1 ; @entity551 [ @entity551 ] <90% of predicted values) were randomly assigned to the experimental (n=11) and control groups (n=10); 18 @entity1 completed all testing and training. INTERVENTIONS: Interventions were based on home-based training, with resistance adjusted biweekly to 30% of @entity551 for the experimental group. The control group underwent the same protocol without the threshold resistance valve. Both groups received home training 30 minutes a day 5 times a week for 8 weeks. MAIN OUTCOME MEASURES: @entity551 , inspiratory muscular endurance (IME), functional performance, and QOL. RESULTS: There were significant between-group differences for the @entity551 and IME measures. Significant changes were observed for only the experimental group for @entity551 (67.8  14.6 at baseline to 102.2  26.0cm @entity2507 at posttraining) and IME (31.8  19.3 to 49.2  21.1cm @entity2507 ). No statistically significant differences were observed for measures of functional performance and QOL. CONCLUSIONS: Significant short-term effects of the IMT program for inspiratory strength and endurance were observed in chronic @entity64 survivors. These findings gave some indications that IMT may benefit @entity1 with @entity64 , and it is feasible to be included in rehabilitation interventions with this population.

title: Inspiratory muscular training in chronic XXXX survivors: a randomized controlled trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'women', 'PARTICIPANTS', 'people', 'men']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['maximal inspiratory pressure', 'MIP']

answer: @entity64 :: (MESH:D020521,Disease) :: ['stroke']


abstract: OBJECTIVES: Aims of this study were to investigate the effect of renal function on left ventricular (LV) reverse remodeling and long-term outcome after cardiac resynchronization therapy (CRT), and to explore the relation between LV reverse remodeling and changes in renal function at 6-month follow-up. BACKGROUND: @entity177 is highly prevalent in @entity712 @entity1 , including @entity1 eligible for CRT, and is associated with poor prognosis. METHODS: The study comprised 490 @entity1 undergoing CRT. Response to CRT was defined as a decrease in LV end-systolic volume >= 15% at 6-month follow-up. Primary end point during long-term follow-up was all-cause mortality. RESULTS: At baseline, mean estimated glomerular filtration rate (eGFR) was 70    28 ml/ @entity1009 .73 m  . At 6-month follow-up, 263 @entity1 (54%) demonstrated response to CRT. Responders had an eGFR of 74    26 ml/ @entity1009 .73 m   versus 64    28 ml/ @entity1009 .73 m   in nonresponders (p < 0.001). During long-term follow-up, @entity1 with an eGFR <60 ml/ @entity1009 .73 m   had higher mortality than @entity1 with an eGFR of 60 to 90 ml/ @entity1009 .73 m   or an eGFR >90 ml/ @entity1009 .73 m   (p < 0.001). Finally, responders to CRT had preservation of renal function (/\eGFR -0.6), whereas nonresponders had a slight worsening in renal function (/\eGFR -4.7, p < 0.05). CONCLUSIONS: @entity8 in CRT candidates is associated with nonresponse during 6-month follow-up. Additionally, @entity1 with @entity8 have worse long-term survival after CRT. Response to CRT results in preservation of renal function.

title: XXXX is associated with echocardiographic nonresponse and poor prognosis after cardiac resynchronization therapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['Impaired renal function', 'impaired renal function']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['heart failure']

entities_list: @entity177 :: ('MESH:D051437', 'Disease') :: ['Renal insufficiency']

answer: @entity8 :: (MESH:D007674,Disease) :: ['Impaired renal function']


abstract: BACKGROUND AND AIM: To report on the prevalence of @entity29 ( @entity29 ) related @entity1944 and @entity5 in northwestern Greece. @entity1 AND METHODS: Single referral center retrospective study. The policy among all gastroenterologists of the area regarding medical treatment, @entity1 follow up and bowel surveillance strategies including risk factors is the same. RESULTS: We analyzed 1494 colonoscopies from 696 consecutive @entity29 @entity1 (494 UC). The follow up time [median, IQR] was 16 [8-23] years and the age at diagnosis was 28 [21-49] years. The number of @entity1 years at risk was 16.219. Disease location for UC was: pancolitis 761 (59%), @entity1960 455 (35%), and @entity4272 69 (6%). Disease location for @entity1050 was: colitis 142 (66%), @entity13570 45 (22%) and @entity30 21 (10%). Disease activity was in remission in 1240 (83%) of them. In total, 498 (72%) @entity1 were on @entity2983 , 169(24%) on immunosuppression and 29 (4%) on biologicals. Biopsies were taken randomly in 1429 (96%) endoscopies and were targeted in 65 (4%) of them. We recorded 69 (9.4%) cases with @entity1141 and 10 (1.4%) cases with @entity5 (9 in UC). No difference was found for @entity1141 and @entity5 in @entity1 who followed up for 10-20 years or for more than 20 years. CONCLUSIONS: The prevalence of @entity1141 and @entity5 is increased in UC compared to @entity1050 but the prevalence of high-grade @entity1141 is comparatively low. @entity5 prevalence is increasing after the first decade and then practically remains stable.

title: Prevalence of @entity29 related XXXX and @entity5 in 1500 colonoscopies from a referral center in northwestern Greece.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS']

entities_list: @entity1944 :: ('MESH:D007410', 'Disease') :: ['intestinal dysplasia']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Intestinal cancer', 'cancer', 'intestinal cancer']

entities_list: @entity4272 :: ('MESH:D011349', 'Disease') :: ['proctitis']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease', 'IBD']

entities_list: @entity1960 :: ('MESH:D003092', 'Disease') :: ['left sided colitis']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ['ileocolitis']

entities_list: @entity2983 :: ('MESH:D019804', 'Chemical') :: ['mesalazine']

entities_list: @entity1141 :: ('MESH:C535662', 'Disease') :: ['dysplasia']

answer: @entity1141 :: (MESH:C535662,Disease) :: ['dysplasia']


abstract: BACKGROUND AND AIM: To report on the prevalence of @entity29 ( @entity29 ) related @entity1944 and @entity5 in northwestern Greece. @entity1 AND METHODS: Single referral center retrospective study. The policy among all gastroenterologists of the area regarding medical treatment, @entity1 follow up and bowel surveillance strategies including risk factors is the same. RESULTS: We analyzed 1494 colonoscopies from 696 consecutive @entity29 @entity1 (494 UC). The follow up time [median, IQR] was 16 [8-23] years and the age at diagnosis was 28 [21-49] years. The number of @entity1 years at risk was 16.219. Disease location for UC was: pancolitis 761 (59%), @entity1960 455 (35%), and @entity4272 69 (6%). Disease location for @entity1050 was: colitis 142 (66%), @entity13570 45 (22%) and @entity30 21 (10%). Disease activity was in remission in 1240 (83%) of them. In total, 498 (72%) @entity1 were on @entity2983 , 169(24%) on immunosuppression and 29 (4%) on biologicals. Biopsies were taken randomly in 1429 (96%) endoscopies and were targeted in 65 (4%) of them. We recorded 69 (9.4%) cases with @entity1141 and 10 (1.4%) cases with @entity5 (9 in UC). No difference was found for @entity1141 and @entity5 in @entity1 who followed up for 10-20 years or for more than 20 years. CONCLUSIONS: The prevalence of @entity1141 and @entity5 is increased in UC compared to @entity1050 but the prevalence of high-grade @entity1141 is comparatively low. @entity5 prevalence is increasing after the first decade and then practically remains stable.

title: Prevalence of XXXX related @entity1141 and @entity5 in 1500 colonoscopies from a referral center in northwestern Greece.

answer: @entity29 :: (MESH:D015212,Disease) :: ['inflammatory bowel disease']


abstract: BACKGROUND AND AIM: To report on the prevalence of @entity29 ( @entity29 ) related @entity1944 and @entity5 in northwestern Greece. @entity1 AND METHODS: Single referral center retrospective study. The policy among all gastroenterologists of the area regarding medical treatment, @entity1 follow up and bowel surveillance strategies including risk factors is the same. RESULTS: We analyzed 1494 colonoscopies from 696 consecutive @entity29 @entity1 (494 UC). The follow up time [median, IQR] was 16 [8-23] years and the age at diagnosis was 28 [21-49] years. The number of @entity1 years at risk was 16.219. Disease location for UC was: pancolitis 761 (59%), @entity1960 455 (35%), and @entity4272 69 (6%). Disease location for @entity1050 was: colitis 142 (66%), @entity13570 45 (22%) and @entity30 21 (10%). Disease activity was in remission in 1240 (83%) of them. In total, 498 (72%) @entity1 were on @entity2983 , 169(24%) on immunosuppression and 29 (4%) on biologicals. Biopsies were taken randomly in 1429 (96%) endoscopies and were targeted in 65 (4%) of them. We recorded 69 (9.4%) cases with @entity1141 and 10 (1.4%) cases with @entity5 (9 in UC). No difference was found for @entity1141 and @entity5 in @entity1 who followed up for 10-20 years or for more than 20 years. CONCLUSIONS: The prevalence of @entity1141 and @entity5 is increased in UC compared to @entity1050 but the prevalence of high-grade @entity1141 is comparatively low. @entity5 prevalence is increasing after the first decade and then practically remains stable.

title: Prevalence of @entity29 related @entity1141 and XXXX in 1500 colonoscopies from a referral center in northwestern Greece.

answer: @entity5 :: (MESH:D009369,Disease) :: ['cancer']


abstract: BACKGROUND: @entity6542 ( @entity6542 ) is the only treatment that interferes with the basic pathophysiological mechanisms of @entity56 and is widely used in the management of clinically significant respiratory IgE-mediated diseases. Nevertheless, until recently, information on the influence of @entity6542 on the development of @entity56 has been scant. METHODS: One hundred consecutive @entity1 (45 males and 55 females, aged 6 to 69 years) with @entity1576 and attending the allergy unit of a general hospital were selected. All had been diagnosed by clinical history and skin prick tests of @entity2023 and/or @entity565 , were monosensitised (71 to Dermatophagoides spp, 22 to Parietaria judaica pollen and 7 to grass pollen) and had been followed up as outpatients between 1990-98. Sixty-six @entity1 had been treated with conventional @entity6542 for at least 3 years, while thirty-four followed only environmental measures and drug treatment. @entity402 status (first-degree relatives), smoking, family pets (cat and/or @entity235 ), @entity2490 and/or @entity565 symptom score and inhalant skin prick tests to the same aeroallergens were compared between baseline and after 3 to 5 years of treatment. RESULTS: No statistically-significant differences in the development of new sensitisations were observed between the two groups (36.4 % of @entity6542 -treated @entity1 versus 38.2 % in control group, RR = 0.97, CI 95 %: 0.72-1.3). Smoking, family atopy history and pets did not appear to be risk factors for the development of neosensitisations (p < 0.05). Nevertheless, @entity6542 -treated @entity1 presented a better clinical score than the control group, with improvements of 89.4 % and 61.8 %, respectively (p = 0.007). CONCLUSIONS: Three-year @entity6542 did not protect against development of new sensitisations in monosensitised @entity2023 or @entity565 . Smoking, family atopy history and pets were not associated with development of new sensitisations. Clinical score improved significantly in the @entity6542 -treated group compared with drug-treated @entity1 .

title: Effects of specific immunotherapy on the development of new sensitisations in monosensitised XXXX .

entities_list: @entity6542 :: ('MESH:C562465', 'Disease') :: ['Specific immunotherapy', 'SIT']

entities_list: @entity2023 :: ('MESH:D006255', 'Disease') :: ['allergic rhinitis']

entities_list: @entity402 :: ('MESH:C564133', 'Disease') :: ['Family atopy']

entities_list: @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic disease', 'new allergic sensitisations']

entities_list: @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory allergic diseases']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: OBJECTIVES: We sought to determine the relationship of contractile function to the transmural extent of @entity1188 (TEI) in @entity1 with chronic @entity453 . BACKGROUND: In the setting of reperfused, chronic @entity583 ( @entity583 ), the relationship of contractile function to the TEI has not been established. METHODS: We studied function by cine magnetic resonance imaging (MRI) and the TEI by contrast-enhanced MRI in 31 @entity1 with @entity66 162 +/- 62 days after reperfused first @entity583 . RESULTS: Of all 516 segments with @entity583 , blinded observers were unable to detect abnormal thickening in 193 (37%), and wall thickening measured quantitatively in these segments was 66 +/- 28%. Of the 193 segments, 163 (84%) were @entity1188 limited to the subendocardium. The average TEI reached 53% before half of the @entity1 had abnormal contractile function. When @entity1 with small @entity583 (< or =5% of total left ventricular [LV] mass) were excluded, the average TEI reached 43% before half the @entity1 had abnormal function. In subjects with small @entity583 (< or =5% of total LV mass [n = 13]), even segments with TEI >75% had normal function (14 of 14) because they were surrounded by normally moving neighbor segments. CONCLUSIONS: In the setting of reperfused chronic @entity583 , the TEI approaches 50% before contractile dysfunction can be systematically identified. Contractile function cannot be used to rule out chronic @entity583 .

title: Relationship of contractile function to transmural extent of XXXX in @entity1 with chronic @entity453 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['myocardial infarction', 'MI']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['single-vessel disease']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarcts', 'infarction']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

answer: @entity1188 :: (MESH:D007238,Disease) :: ['infarction']


abstract: OBJECTIVES: We sought to determine the relationship of contractile function to the transmural extent of @entity1188 (TEI) in @entity1 with chronic @entity453 . BACKGROUND: In the setting of reperfused, chronic @entity583 ( @entity583 ), the relationship of contractile function to the TEI has not been established. METHODS: We studied function by cine magnetic resonance imaging (MRI) and the TEI by contrast-enhanced MRI in 31 @entity1 with @entity66 162 +/- 62 days after reperfused first @entity583 . RESULTS: Of all 516 segments with @entity583 , blinded observers were unable to detect abnormal thickening in 193 (37%), and wall thickening measured quantitatively in these segments was 66 +/- 28%. Of the 193 segments, 163 (84%) were @entity1188 limited to the subendocardium. The average TEI reached 53% before half of the @entity1 had abnormal contractile function. When @entity1 with small @entity583 (< or =5% of total left ventricular [LV] mass) were excluded, the average TEI reached 43% before half the @entity1 had abnormal function. In subjects with small @entity583 (< or =5% of total LV mass [n = 13]), even segments with TEI >75% had normal function (14 of 14) because they were surrounded by normally moving neighbor segments. CONCLUSIONS: In the setting of reperfused chronic @entity583 , the TEI approaches 50% before contractile dysfunction can be systematically identified. Contractile function cannot be used to rule out chronic @entity583 .

title: Relationship of contractile function to transmural extent of @entity1188 in @entity1 with chronic XXXX .

answer: @entity453 :: (MESH:D003324,Disease) :: ['coronary artery disease']


abstract: OBJECTIVES: We sought to determine the relationship of contractile function to the transmural extent of @entity1188 (TEI) in @entity1 with chronic @entity453 . BACKGROUND: In the setting of reperfused, chronic @entity583 ( @entity583 ), the relationship of contractile function to the TEI has not been established. METHODS: We studied function by cine magnetic resonance imaging (MRI) and the TEI by contrast-enhanced MRI in 31 @entity1 with @entity66 162 +/- 62 days after reperfused first @entity583 . RESULTS: Of all 516 segments with @entity583 , blinded observers were unable to detect abnormal thickening in 193 (37%), and wall thickening measured quantitatively in these segments was 66 +/- 28%. Of the 193 segments, 163 (84%) were @entity1188 limited to the subendocardium. The average TEI reached 53% before half of the @entity1 had abnormal contractile function. When @entity1 with small @entity583 (< or =5% of total left ventricular [LV] mass) were excluded, the average TEI reached 43% before half the @entity1 had abnormal function. In subjects with small @entity583 (< or =5% of total LV mass [n = 13]), even segments with TEI >75% had normal function (14 of 14) because they were surrounded by normally moving neighbor segments. CONCLUSIONS: In the setting of reperfused chronic @entity583 , the TEI approaches 50% before contractile dysfunction can be systematically identified. Contractile function cannot be used to rule out chronic @entity583 .

title: Relationship of contractile function to transmural extent of @entity1188 in XXXX with chronic @entity453 .

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: BACKGROUND: Coagulation plays an important part in @entity65 . Results of studies have shown that extremes in hypocoagulability protect against @entity65 . We have investigated overall mortality and @entity204 from cardiovascular causes in carriers of @entity447 , who in most cases have mildly @entity3459 without clinical signs. METHODS: We followed-up a cohort of 1012 mothers of all known @entity1 with @entity447 in the Netherlands from birth to @entity204 , or the end-of-study date (41984 @entity1 years of follow-up). We obtained vital status and causes of @entity204 , if deceased, and compared overall and cause-specific mortality in our cohort with that in the general Dutch female population adjusted for age and calendar period by calculating the standardised mortality ratio (SMR). FINDINGS: Overall mortality was reduced by 22% (261 observed @entity204 , 333.74 expected; SMR 0.78 [95% CI 0.69-0.88]). @entity204 from @entity299 were reduced by 36% (39 observed @entity204 , 60.53 expected; SMR 0.64 [0.47-0.88]). We did not note decreased mortality for @entity64 (ischaemic and @entity548 combined) (28 observed @entity204 , 36.82 expected; SMR 0.76 [0.53-1.10]). A separate analysis of these two types of @entity64 was not possible. @entity1 in our cohort had an increased risk of @entity204 from extracranial @entity548 (5 observed @entity204 , 0.18 expected; SMR 27.78 [8.49-58.18]); however, the number of @entity204 from this cause was much lower than that for @entity299 . CONCLUSION: The results show that a mild @entity3459 has a protective effect against fatal @entity299 .

title: Decreased mortality of @entity299 among carriers of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Women', 'person', 'people']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'cerebral stroke']

entities_list: @entity548 :: ('MESH:D006470', 'Disease') :: ['haemorrhage', 'haemorrhagic']

entities_list: @entity447 :: ('MESH:D006467', 'Disease') :: ['haemophilia']

entities_list: @entity3459 :: ('MESH:D025861', 'Disease') :: ['decrease in coagulability', 'decreased coagulability']

entities_list: @entity299 :: ('MESH:D006331', 'Disease') :: ['ischaemic heart disease']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['Deaths', 'death', 'deaths']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['ischaemic cardiovascular disease']

answer: @entity447 :: (MESH:D006467,Disease) :: ['haemophilia']


abstract: BACKGROUND: Coagulation plays an important part in @entity65 . Results of studies have shown that extremes in hypocoagulability protect against @entity65 . We have investigated overall mortality and @entity204 from cardiovascular causes in carriers of @entity447 , who in most cases have mildly @entity3459 without clinical signs. METHODS: We followed-up a cohort of 1012 mothers of all known @entity1 with @entity447 in the Netherlands from birth to @entity204 , or the end-of-study date (41984 @entity1 years of follow-up). We obtained vital status and causes of @entity204 , if deceased, and compared overall and cause-specific mortality in our cohort with that in the general Dutch female population adjusted for age and calendar period by calculating the standardised mortality ratio (SMR). FINDINGS: Overall mortality was reduced by 22% (261 observed @entity204 , 333.74 expected; SMR 0.78 [95% CI 0.69-0.88]). @entity204 from @entity299 were reduced by 36% (39 observed @entity204 , 60.53 expected; SMR 0.64 [0.47-0.88]). We did not note decreased mortality for @entity64 (ischaemic and @entity548 combined) (28 observed @entity204 , 36.82 expected; SMR 0.76 [0.53-1.10]). A separate analysis of these two types of @entity64 was not possible. @entity1 in our cohort had an increased risk of @entity204 from extracranial @entity548 (5 observed @entity204 , 0.18 expected; SMR 27.78 [8.49-58.18]); however, the number of @entity204 from this cause was much lower than that for @entity299 . CONCLUSION: The results show that a mild @entity3459 has a protective effect against fatal @entity299 .

title: Decreased mortality of XXXX among carriers of @entity447 .

answer: @entity299 :: (MESH:D006331,Disease) :: ['ischaemic heart disease']


abstract: The aim of the present study was to clarify the involvement of protein kinase Cy (PKCy) in the facial @entity9 following @entity128 . We analyzed the change in PKCy expression in the trigeminal spinal subnucleus caudalis (Vc) and upper cervical spinal cord ( @entity72766 ) following chronic @entity128 (ION-CCI). We also studied ION-CCI-mediated mechanical nocifensive behavior in @entity35 . The mechanical head-withdrawal threshold significantly decreased 1 to 14 days after ION-CCI compared with that before ION-CCI and in sham @entity35 . The expression of PKCy was significantly larger in the ipsilateral Vc compared with the contralateral side in ION-CCI @entity35 3, 7, and 14 days after ION-CCI. Intrathecal (i.t.) administration of the PKCy inhibitor @entity668 prevented an increase in the PKCy expression in the ipsilateral Vc. Moreover, i.t. administration of @entity668 annulled ION-CCI-mediated reduction in the head-withdrawal threshold. Taken together, these findings suggest that PKCy expression in the Vc played an important role in the mechanism of orofacial static mechanical @entity1931 following @entity7198 .

title: PKCgamma in Vc and @entity72766 is involved in trigeminal XXXX .

entities_list: @entity1931 :: ('MESH:D006930', 'Disease') :: ['allodynia']

entities_list: @entity7198 :: ('MESH:D061221', 'Disease') :: ['trigeminal nerve injury']

entities_list: @entity668 :: ('MESH:C016299', 'Chemical') :: ['chelerythrine']

entities_list: @entity128 :: ('MESH:D020209', 'Disease') :: ['infraorbital nerve injury', 'constriction injury of the infraorbital nerve']

entities_list: @entity9 :: ('MESH:D009437', 'Disease') :: ['neuropathic pain']

answer: @entity9 :: (MESH:D009437,Disease) :: ['neuropathic pain']


abstract: The aim of the present study was to clarify the involvement of protein kinase Cy (PKCy) in the facial @entity9 following @entity128 . We analyzed the change in PKCy expression in the trigeminal spinal subnucleus caudalis (Vc) and upper cervical spinal cord ( @entity72766 ) following chronic @entity128 (ION-CCI). We also studied ION-CCI-mediated mechanical nocifensive behavior in @entity35 . The mechanical head-withdrawal threshold significantly decreased 1 to 14 days after ION-CCI compared with that before ION-CCI and in sham @entity35 . The expression of PKCy was significantly larger in the ipsilateral Vc compared with the contralateral side in ION-CCI @entity35 3, 7, and 14 days after ION-CCI. Intrathecal (i.t.) administration of the PKCy inhibitor @entity668 prevented an increase in the PKCy expression in the ipsilateral Vc. Moreover, i.t. administration of @entity668 annulled ION-CCI-mediated reduction in the head-withdrawal threshold. Taken together, these findings suggest that PKCy expression in the Vc played an important role in the mechanism of orofacial static mechanical @entity1931 following @entity7198 .

title: PKCgamma in Vc and XXXX is involved in trigeminal @entity9 .

answer: @entity72766 :: (24231(Tax:10116),Gene) :: ['C1/C2']


abstract: BACKGROUND: The aim of this study was to assess the salivary content of lipid peroxidation and antioxidants in @entity1 with @entity164 2 @entity6 . METHOD: We studied 25 @entity1 with @entity164 2 @entity6 and other 25 age- and sex-matched health control. To evaluate the oxidative status we measured the levels of @entity1234 ( @entity1865 ) in the saliva and serum of all @entity1 . Lipid profile was also estimated through measuring total @entity165 , @entity1674 , low-density lipoprotein @entity165 (LDL-C), high-density lipoprotein @entity165 (HDL-C) and very low-density lipoprotein @entity165 (VLDL-C) levels. Antioxidant levels were also assessed through measuring the salivary and serum concentration of @entity414 , @entity224 dismutase and @entity2041 ( @entity2197 ). RESULTS: The high concentration of lipid fractions in saliva usually follows that recorded in serum. Salivary @entity1865 levels, a product of lipid peroxidation, were significantly increased among diabetics together with @entity414 . However, @entity2197 levels were similar to those of the control group. CONCLUSION: Lipid peroxidation and antioxidant parameters assessed in saliva of @entity6 @entity1 may be of great importance in evaluating the disease activity and severity. The increase in lipid peroxidation and the tendency of antioxidants to rise in @entity6 is probably due to an adaptive response to the pro-oxidant status of @entity6 .

title: Oxidative stress, antioxidant status and lipid profile in the saliva of XXXX 2 diabetics.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'patients']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']

entities_list: @entity1674 :: ('MESH:D014280', 'Chemical') :: ['triglycerides']

entities_list: @entity2041 :: ('MESH:D005978', 'Chemical') :: ['reduced glutathione']

entities_list: @entity1234 :: ('MESH:D008315', 'Chemical') :: ['malondialdehyde']

entities_list: @entity224 :: ('MESH:D013481', 'Chemical') :: ['superoxide']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']

answer: @entity164 :: (MESH:D017827,Disease) :: ['type']


abstract: OBJECTIVES: @entity3131 (Deskar, Marnac Inc., Dallas, TX), @entity3131 , is a broad-spectrum, noncytotoxic, oral antifibrotic agent that is reported to inhibit or block the action of cytokine growth factors: transforming growth factor beta1, platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor, and to prevent formation of new @entity75 . METHODS: We enrolled 10 @entity1 and four @entity1 with extensive @entity1412 ( @entity1412 )-associated @entity8977 in a 2-yr open-label treatment trial with oral @entity3131 . Imaging of desmoids was conducted at baseline and 6, 12, and 24 months. RESULTS: No drug @entity137 or drug intolerance was encountered. Seven @entity1 dropped out (three because of @entity74 ), and seven continued for at least 18 months. Of those that continued, two had partial but significant reduction in the size of all desmoids beginning in the first 6 months of treatment, and two others experienced relief of symptoms without change in desmoid size. Three @entity1 experienced no change in @entity5 size or symptoms. CONCLUSIONS: @entity3131 is well tolerated by @entity1 with @entity1412 -associated @entity765 . Some @entity1 with @entity1412 treated with @entity3131 had regression of @entity5 , some had progression, and some had no response. @entity1 with rapidly growing @entity5 did not respond to @entity3131 . A placebo-controlled trial is needed to determine whether there is a subset of @entity1 for whom @entity3131 may result in partial shrinkage of @entity765 , because the natural history of @entity765 is not predictable or understood.

title: @entity765 in XXXX : a pilot project evaluating efficacy of treatment with @entity3131 .

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients', 'men']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['fibrotic lesions']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors']

entities_list: @entity765 :: ('MESH:D018222', 'Disease') :: ['desmoid tumors']

entities_list: @entity3131 :: ('MESH:C093844', 'Chemical') :: ['5-methyl-1-phenyl-2-(1H)-pyridone', 'Pirfenidone', 'pirfenidone']

entities_list: @entity8977 :: ('MESH:C535944', 'Disease') :: ['desmoid disease']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['progressive disease']

entities_list: @entity1412 :: ('MESH:D011125', 'Disease') :: ['FAP/desmoid tumors', 'familial adenomatous polyposis', 'FAP']

answer: @entity1412 :: (MESH:D011125,Disease) :: ['familial adenomatous polyposis']


abstract: OBJECTIVES: @entity3131 (Deskar, Marnac Inc., Dallas, TX), @entity3131 , is a broad-spectrum, noncytotoxic, oral antifibrotic agent that is reported to inhibit or block the action of cytokine growth factors: transforming growth factor beta1, platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor, and to prevent formation of new @entity75 . METHODS: We enrolled 10 @entity1 and four @entity1 with extensive @entity1412 ( @entity1412 )-associated @entity8977 in a 2-yr open-label treatment trial with oral @entity3131 . Imaging of desmoids was conducted at baseline and 6, 12, and 24 months. RESULTS: No drug @entity137 or drug intolerance was encountered. Seven @entity1 dropped out (three because of @entity74 ), and seven continued for at least 18 months. Of those that continued, two had partial but significant reduction in the size of all desmoids beginning in the first 6 months of treatment, and two others experienced relief of symptoms without change in desmoid size. Three @entity1 experienced no change in @entity5 size or symptoms. CONCLUSIONS: @entity3131 is well tolerated by @entity1 with @entity1412 -associated @entity765 . Some @entity1 with @entity1412 treated with @entity3131 had regression of @entity5 , some had progression, and some had no response. @entity1 with rapidly growing @entity5 did not respond to @entity3131 . A placebo-controlled trial is needed to determine whether there is a subset of @entity1 for whom @entity3131 may result in partial shrinkage of @entity765 , because the natural history of @entity765 is not predictable or understood.

title: @entity765 in @entity1412 : a pilot project evaluating efficacy of treatment with XXXX .

answer: @entity3131 :: (MESH:C093844,Chemical) :: ['pirfenidone']


abstract: OBJECTIVES: @entity3131 (Deskar, Marnac Inc., Dallas, TX), @entity3131 , is a broad-spectrum, noncytotoxic, oral antifibrotic agent that is reported to inhibit or block the action of cytokine growth factors: transforming growth factor beta1, platelet-derived growth factor, epidermal growth factor, and fibroblast growth factor, and to prevent formation of new @entity75 . METHODS: We enrolled 10 @entity1 and four @entity1 with extensive @entity1412 ( @entity1412 )-associated @entity8977 in a 2-yr open-label treatment trial with oral @entity3131 . Imaging of desmoids was conducted at baseline and 6, 12, and 24 months. RESULTS: No drug @entity137 or drug intolerance was encountered. Seven @entity1 dropped out (three because of @entity74 ), and seven continued for at least 18 months. Of those that continued, two had partial but significant reduction in the size of all desmoids beginning in the first 6 months of treatment, and two others experienced relief of symptoms without change in desmoid size. Three @entity1 experienced no change in @entity5 size or symptoms. CONCLUSIONS: @entity3131 is well tolerated by @entity1 with @entity1412 -associated @entity765 . Some @entity1 with @entity1412 treated with @entity3131 had regression of @entity5 , some had progression, and some had no response. @entity1 with rapidly growing @entity5 did not respond to @entity3131 . A placebo-controlled trial is needed to determine whether there is a subset of @entity1 for whom @entity3131 may result in partial shrinkage of @entity765 , because the natural history of @entity765 is not predictable or understood.

title: XXXX in @entity1412 : a pilot project evaluating efficacy of treatment with @entity3131 .

answer: @entity765 :: (MESH:D018222,Disease) :: ['Desmoid tumors']


abstract: PURPOSE: To report our experience with @entity13850 in 2nd-, 3rd- and 4th-line therapy for @entity1 with @entity1358 ( @entity1358 ). @entity1 AND METHODS: In our prospectively maintained @entity5 registry, we identified 6 @entity1358 @entity1 with @entity13850 in >1st-line systemic therapy. @entity1 were followed by weekly clinical and laboratory examination during admission of @entity13850 . Re-staging with chest CT and abdominal MRI was performed every 3 months. RESULTS: We observed excellent response rates. Progression-free survival (PFS) ranged from 6 to 40 months with a median of 15 months. Treatment was generally well tolerated. However, @entity55 was observed in 4 of 6 @entity1 . Drug-related @entity55 led to severe @entity1353 , with the result that treatment with @entity13850 had to be interrupted for a short period of time in 2 @entity1 and discontinued in 1 @entity1 . CONCLUSIONS: @entity13850 proved to be a very good treatment option in 2nd- to 4th-line therapy with excellent response rates and manageable side effects. The incidence of @entity55 must not be underestimated.

title: Initial experience with @entity13850 in 2nd-, 3rd- and 4th-line therapy for metastatic XXXX : good clinical response.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient', 'PATIENTS']

entities_list: @entity13850 :: ('MESH:C401859', 'Chemical') :: ['temsirolimus', 'Temsirolimus']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['mRCC', 'metastatic renal cell carcinoma']

answer: @entity1358 :: (MESH:D002292,Disease) :: ['renal cell cancer']


abstract: PURPOSE: To report our experience with @entity13850 in 2nd-, 3rd- and 4th-line therapy for @entity1 with @entity1358 ( @entity1358 ). @entity1 AND METHODS: In our prospectively maintained @entity5 registry, we identified 6 @entity1358 @entity1 with @entity13850 in >1st-line systemic therapy. @entity1 were followed by weekly clinical and laboratory examination during admission of @entity13850 . Re-staging with chest CT and abdominal MRI was performed every 3 months. RESULTS: We observed excellent response rates. Progression-free survival (PFS) ranged from 6 to 40 months with a median of 15 months. Treatment was generally well tolerated. However, @entity55 was observed in 4 of 6 @entity1 . Drug-related @entity55 led to severe @entity1353 , with the result that treatment with @entity13850 had to be interrupted for a short period of time in 2 @entity1 and discontinued in 1 @entity1 . CONCLUSIONS: @entity13850 proved to be a very good treatment option in 2nd- to 4th-line therapy with excellent response rates and manageable side effects. The incidence of @entity55 must not be underestimated.

title: Initial experience with XXXX in 2nd-, 3rd- and 4th-line therapy for metastatic @entity1358 : good clinical response.

answer: @entity13850 :: (MESH:C401859,Chemical) :: ['temsirolimus']


abstract: Based on the favorable safety profile and the independent activity of rituximab in @entity1892 , we evaluated its efficacy and @entity137 after @entity34 ( @entity34 ) and autologous hematopoietic cell transplantation (HCT). Thirty-five @entity1 with diffuse large cell (25 @entity1 ), mantle cell (3 @entity1 ), transformed (3 @entity1 ), or other (4 @entity1 ) subtypes of @entity1892 received @entity34 followed by a purged autologous graft. The rituximab schedule was 4 weekly infusions (375 mg/m(2)) starting at day 42 after HCT and, for @entity1 5 to 35, a second 4-week course 6 months after HCT. All planned therapy was completed in 29 @entity1 . With 30 months' median follow-up, the 2-year event-free survival (EFS) rate was 83% and the @entity1349 ( @entity1349 ) rate was 88%. For 21 @entity1 with relapsed or @entity706 , the EFS rate was 81% and the @entity1349 rate was 85%. Grades 3 to 4 @entity1398 occurred in 19 (54%) @entity1 . A prospective study of immune reconstitution included measurements of lymphocyte subsets, immunoglobulins, and response to vaccination. Serious infections were not observed despite delayed B-cell recovery in all @entity1 and suppressed immunoglobulin G (IgG) levels and low pneumococcus antibody titers in a subset. Rituximab after @entity34 and HCT is feasible, and these phase 2 data support the current US Intergroup phase 3 trial in recurrent/refractory @entity4812 .

title: Rituximab as adjuvant to XXXX and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['refractory large cell lymphoma']

entities_list: @entity4812 :: ('MESH:D016403', 'Disease') :: ['diffuse large cell lymphoma']

entities_list: @entity1892 :: ('MESH:D016393', 'Disease') :: ['B-cell lymphoma']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

entities_list: @entity34 :: ('MESH:D016609', 'Disease') :: ['high-dose therapy', 'HDT']

answer: @entity34 :: (MESH:D016609,Disease) :: ['high-dose therapy']


abstract: BACKGROUND: Behavioral dyscontrol and violations of treatment contracts are serious clinical problems during psychotherapy, especially in treating @entity1 with @entity1314 . However, little is known about predictors of these treatment-interfering phenomena. OBJECTIVE: To identify psychodynamic personality characteristics that can interfere with the psychotherapy process as indicated by treatment-disrupting behaviors. METHODS: Sociodemographic characteristics, descriptive psychiatric diagnoses, and psycho-dynamic characteristics were assessed in 89 inpatients with @entity1314 in psychotherapeutic treatment. Psychodynamic characteristics were assessed with the Develop mental Profile (DP). DP variables were used to predict impulsive acts, anger outbursts, para-suicidal behaviors, and contract violations. Incremental value was established. RESULTS: In this sample, 4 out of 5 @entity1 engaged in treatment-interfering behaviors during the first 3 months of therapy. In general, treatment-disrupting behaviors were not predicted by baseline DSM-IV @entity74 . In contrast, @entity146 , anger outbursts, and contract violations were significantly predicted by psychodynamic variables, especially the DP levels Fragmentation and Egocentricity. DP variables accounted for an incremental predictive value of 23% for treatment-disrupting behaviors, over and above demographics and descriptive diagnoses. Para-suicidal gestures were not predicted by either DSM-IV diagnoses or psychodynamic variables. CONCLUSION: Psychodynamic personality variables significantly predicted @entity146 , outbursts of anger, and treatment contract violations during psychotherapeutic treatment. The amount of explained variance and incremental value was substantial. These findings support the relevance of psychodynamic assessment in clinical practice. (Journal of Psychiatric Practice. 2011;17:21-34).

title: Treatment-disrupting behaviors during psychotherapy of @entity1 with XXXX : the predictive power of psychodynamic personality diagnosis.

entities_list: @entity1314 :: ('MESH:D010554', 'Disease') :: ['personality disorders']

entities_list: @entity74 :: ('MESH:D030342', 'Disease') :: ['Axis I or II disorders']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['impulsive behaviors']

answer: @entity1314 :: (MESH:D010554,Disease) :: ['personality disorders']


abstract: BACKGROUND: Behavioral dyscontrol and violations of treatment contracts are serious clinical problems during psychotherapy, especially in treating @entity1 with @entity1314 . However, little is known about predictors of these treatment-interfering phenomena. OBJECTIVE: To identify psychodynamic personality characteristics that can interfere with the psychotherapy process as indicated by treatment-disrupting behaviors. METHODS: Sociodemographic characteristics, descriptive psychiatric diagnoses, and psycho-dynamic characteristics were assessed in 89 inpatients with @entity1314 in psychotherapeutic treatment. Psychodynamic characteristics were assessed with the Develop mental Profile (DP). DP variables were used to predict impulsive acts, anger outbursts, para-suicidal behaviors, and contract violations. Incremental value was established. RESULTS: In this sample, 4 out of 5 @entity1 engaged in treatment-interfering behaviors during the first 3 months of therapy. In general, treatment-disrupting behaviors were not predicted by baseline DSM-IV @entity74 . In contrast, @entity146 , anger outbursts, and contract violations were significantly predicted by psychodynamic variables, especially the DP levels Fragmentation and Egocentricity. DP variables accounted for an incremental predictive value of 23% for treatment-disrupting behaviors, over and above demographics and descriptive diagnoses. Para-suicidal gestures were not predicted by either DSM-IV diagnoses or psychodynamic variables. CONCLUSION: Psychodynamic personality variables significantly predicted @entity146 , outbursts of anger, and treatment contract violations during psychotherapeutic treatment. The amount of explained variance and incremental value was substantial. These findings support the relevance of psychodynamic assessment in clinical practice. (Journal of Psychiatric Practice. 2011;17:21-34).

title: Treatment-disrupting behaviors during psychotherapy of XXXX with @entity1314 : the predictive power of psychodynamic personality diagnosis.

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: @entity859 modulates various vascular functions such as vasodilatation and anti- @entity32 . The local concentration of @entity859 in the vicinity of @entity859 receptors is fine tuned by 2 classes of @entity2353 transporters: equilibrative @entity2353 transporters (ENTs) and concentrative @entity2353 transporters (CNTs). In vascular smooth muscle cells, 95% of @entity859 transport is mediated by @entity11573 and the rest by @entity13545 . In endothelial cells, 60%, 10%, and 30% of @entity859 transport are mediated by @entity11573 , @entity13545 , and @entity13544 , respectively. In vitro studies show that @entity413 per se increases the expression level of @entity11573 via mitogen-activating protein kinase-dependent pathways. Similar results have been demonstrated in @entity6 animal models. @entity101 is associated with the increased expression of @entity13544 . It has been speculated that the increase in the activities of @entity11573 and @entity13544 may reduce the availability of @entity859 to @entity859 receptors, thereby weakening the vascular functions of @entity859 . This may explain why @entity1 with @entity6 and @entity101 suffer greater morbidity from @entity63 and @entity731 . No oral hypoglycemic agents can inhibit ENTs, but an exception is @entity4506 (a @entity12585 that has been withdrawn from the market). ENTs are also sensitive to @entity7236 -type @entity460 -channel blockers, particularly @entity3931 , which can inhibit @entity11573 in the nanomolar range. Those @entity460 -channel blockers are noncompetitive inhibitors of ENTs, probably working through the reversible interactions with allosteric sites. The nonsteroidal anti-inflammatory drug sulindac @entity3287 is a competitive inhibitor of @entity11573 . In addition to their original pharmacological actions, it is believed that the drugs mentioned above may regulate vascular functions through potentiation of the effects of @entity859 .

title: Physiological and pharmacological roles of vascular XXXX transporters.

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity2353 :: ('CHEBI:33838', 'Chemical') :: ['nucleoside']

entities_list: @entity859 :: ('MESH:D000241', 'Chemical') :: ['Adenosine', 'adenosine']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension', 'Hypertension']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis']

entities_list: @entity4506 :: ('MESH:C057693', 'Chemical') :: ['troglitazone']

entities_list: @entity12585 :: ('MESH:C089946', 'Chemical') :: ['thiazolidinedione']

entities_list: @entity7236 :: ('MESH:C038806', 'Chemical') :: ['dihydropyridine']

entities_list: @entity3931 :: ('MESH:D009553', 'Chemical') :: ['nimodipine']

entities_list: @entity460 :: ('MESH:D002118', 'Chemical') :: ['calcium']

entities_list: @entity3287 :: ('CHEBI:26822', 'Chemical') :: ['sulfide']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity2353 :: (CHEBI:33838,Chemical) :: ['nucleoside']


abstract: BACKGROUND AND OBJECTIVE: The serum paraoxonase and arylesterase activities are related to @entity453 . However, there are a few data about the association of paraoxonase and arylesterase activities with in-stent @entity256 (ISR). The aim of this study was to evaluate the relationship between paraoxonase and arylesterase activities and ISR in @entity1 with bare metal stent (BMS). MATERIALS AND METHODS: Thirty-one @entity1 with normal coronary artery (group 1) and 60 with BMS were enrolled in this observational study. According to the ISR, the @entity1 were classified as group 2, without the ISR (n=29) and group 3, with the ISR (n=31). Serum paraoxonase and arylesterase activities were measured spectrophotometrically. RESULTS: The paraoxonase and arylesterase activities were lower in @entity1 with BMS than in the individuals with normal coronary artery (P < 0.001 and P = 0.001, respectively). The enzyme activities were also higher in @entity1 without ISR than with ISR (both of P < 0.001). In bivariate correlation analyses in @entity1 with BMS, ISR shows significant positive correlations with the presence of @entity101 and @entity407 , @entity75 , and stent length, but shows negative correlations with @entity75 stent diameter, high-density lipoprotein @entity165 , and paraoxonase and arylesterase activities. In regression analysis, ISR is independently associated with paraoxonase and arylesterase activities (b = -0.216, P = 0.038 and b = -0.452, P < 0.001, respectively), @entity75 (b = -0.251, P = 0.013), and stent diameter (b = -0.192, P = 0.024) in @entity1 with BMS. CONCLUSION: Our study shows that decreased paraoxonase and arylesterase activities play a significant role in ethiopathogenesis ISR in @entity1 with BMS.

title: Paraoxonase and arylesterase activities in stent XXXX in bare metal stent.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity407 :: ('MESH:D006949', 'Disease') :: ['hyperlipidemia']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['type C lesion', 'type A lesion']

entities_list: @entity256 :: ('MESH:D023903', 'Disease') :: ['restenosis']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery diseases']

entities_list: @entity165 :: ('MESH:D002784', 'Chemical') :: ['cholesterol']

answer: @entity256 :: (MESH:D023903,Disease) :: ['restenosis']


abstract: STUDY DESIGN: Biomechanics of @entity1 intervertebral discs before and after nucleotomy. OBJECTIVE: To noninvasively quantify the effect of nucleotomy on internal strains under axial compression in flexion, neutral, and extension positions, and to determine whether the change in strains depended on degeneration. SUMMARY OF BACKGROUND DATA: Herniation and nucleotomy may accelerate the progression of @entity1797 . Removal of nucleus pulposus (NP) tissue has resulted in altered disc mechanics in vitro, including a decrease in internal pressure and an increase in the deformations at physiologically relevant strains. We recently presented a technique to quantify internal disc strains using magnetic resonance imaging (MRI). METHODS: Degeneration was quantitatively assessed by the T1   relaxation time in the NP. Samples were prepared from @entity1 levels L3-L4 and/or L4-L5. A 1000-N compressive load was applied while in the magnetic resonance scanner. Nucleotomy was performed by removing 2 g of NP through the posterior-lateral annulus fibrosus (AF). The discs were rehydrated, reimaged, and retested. The analyzed parameters include @entity85 , AF radial bulge, and strains. RESULTS.: The @entity85 was more compressive after nucleotomy. In the neutral position, the @entity85 after nucleotomy correlated with degeneration (as quantified by T1   in the NP), with minimal alteration in nondegenerated discs. Nucleotomy altered the radial displacements and strains in the neutral position, such that the inner AF radial bulge decreased and the radial strains were more tensile in the lateral AF and less tensile in the posterior AF. In the bending loading positions the radial strains were not affected by nucleotomy. CONCLUSION: Nucleotomy alters the internal radial and axial AF strains in the neutral position, which may leave the AF vulnerable to damage and microfractures. In bending, the effects of nucleotomy were minimal, likely due to more of the applied load being directed over the AF. Some of the nucleotomy effects are modulated by degeneration, where the mechanical effect of nucleotomy was magnified in degenerated discs and may further induce mechanical damage and degeneration.

title: The effect of nucleotomy and the dependence of degeneration of XXXX intervertebral disc strain in axial compression.

entities_list: @entity85 :: ('MESH:D009140', 'Disease') :: ['axial deformation']

entities_list: @entity1797 :: ('MESH:D055959', 'Disease') :: ['disc degeneration']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: Limited data exist regarding the long-term outcomes of EMR compared with gastrectomy. OBJECTIVE: To compare the long-term outcomes after EMR and surgery. DESIGN: Retrospective analysis with propensity-score matching. SETTING: Tertiary care center. @entity1 : This study involved 215 @entity1 with @entity356 completely removed by EMR and 843 @entity1 who underwent curative surgical resection between January 1997 and August 2002. Propensity-score matching yielded 551 matched @entity1 . INTERVENTIONS: EMR versus surgery. MAIN OUTCOME MEASUREMENTS: Death and recurrence. RESULTS: In the matched cohort, there were no significant between-group differences in the risk of @entity204 (hazard ratio [HR] for the EMR group 1.39; 95% CI, 0.87-2.23) or recurrence (HR 1.18; 95% CI, 0.22-6.35). Although @entity1 who underwent EMR had higher risk of metachronous @entity356 (HR 6.72; 95% CI, 2.00-22.58), all recurrent or metachronous @entity356 after EMR were successfully re-treated without affecting overall survival. Although complication rates were similar (odds ratio 0.84; 95% CI, 0.41-1.70), there were no mortalities in the EMR group compared with 2 in the surgery group. The EMR group had a significantly shorter hospital stay (median 8 days, interquartile range [IQR] 6-11 days vs 15 days, IQR 12-19 days; P<.001) and lower cost of care ( 2049, IQR  1586-2425 vs  4042, IQR  3458-4959; P<.001). LIMITATIONS: Retrospective, nonrandomized study. CONCLUSIONS: EMR was comparable to surgery in terms of risk of @entity204 and recurrence. Because of its lower medical costs and shorter duration of hospital stay, EMR has advantages over surgery.

title: EMR versus gastrectomy for XXXX : comparison of long-term outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['intramucosal gastric cancer', 'gastric cancers']

answer: @entity356 :: (MESH:D013274,Disease) :: ['intramucosal gastric cancer']


abstract: BACKGROUND: The influence of regional right ventricular (RV) dysfunction on the accuracy of Doppler tissue imaging (DTI) assessment of global RV function is unknown. The objective of this study was to determine the effect of regional dysfunction of the @entity3585 ( @entity3585 ) on the correlations between RV DTI indices and cardiac magnetic resonance (CMR) measurements of global RV function in @entity1 with repaired tetralogy of Fallot. METHODS: Consecutive @entity1 with repaired tetralogy of Fallot who underwent echocardiography with DTI of the right ventricle and CMR within 4 weeks of each other were retrospectively analyzed. RV DTI measurements were obtained from the lateral wall at the level of the tricuspid valve annulus. CMR measurements included end-diastolic and end-systolic volumes, @entity64 volume, and ejection fraction (EF) of the entire right ventricle and measured separately for the RV sinus and @entity3585 segments. RESULTS: The median age of the 51 @entity1 included was 19 years (range, 9.7-71.6 years), and the median interval between echocardiography and CMR was 0 days. The mean RV free wall peak S', isovolumic acceleration, and global, sinus, and @entity3585 EFs were 8.4    2.0 cm/s, 102    37 cm/s(2), and 46.1    9.8%, 47.9    9.9%, and 33    13.1%, respectively. The correlation between peak S' and global RV EF was weak (r  = 0.23) in @entity1 with @entity409 ( @entity3585 EF <30%) but higher (r  = 0.66) in those with @entity3585 EFs >= 30%. Peak S' >= 8.4 cm/s (area under the receiver operating characteristic curve, 0.77) and isovolumic acceleration >= 95 cm/s(2) (area under the receiver operating characteristic curve, 0.68) best discriminated between @entity1 with global RV EFs >45% and <45%. CONCLUSIONS: In this group of @entity1 with repaired TOF, RV DTI indices showed reasonable correlation with CMR-derived global RV EF, but this correlation was substantially weaker in those with moderate and severe dysfunction of the @entity3585 . Peak S' <8.4 cm/s and isovolumic acceleration <95cm/s(2) by DTI should prompt an evaluation of RV function by CMR.

title: Regional dysfunction of the right ventricular outflow tract reduces the accuracy of Doppler tissue imaging assessment of global right ventricular systolic function in XXXX with repaired tetralogy of Fallot.

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['RVOT dysfunction']

entities_list: @entity3585 :: ('MESH:D014694', 'Disease') :: ['RVOT', 'RV outflow tract']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: @entity4008 is frequently fatal or leads to severe @entity16 . Complications such as @entity1333 , resulting in @entity1188 , should be anticipated and dealt with promptly. Our aim was to demonstrate the complications of @entity693 by @entity353 ( @entity353 ) in @entity1 who deteriorated despite therapy. We studied 13 @entity1 between the ages of 1 day and 32 months who presented with symptoms ranging from @entity221 and @entity391 to @entity410 , @entity75 and @entity772 due to @entity4008 , performing MRI, including @entity353 , 2-5 days after presentation. @entity1188 were found on @entity353 in 12 of the 13, most commonly in the frontal lobes (in 10). Global involvement was seen in four @entity1 , three of whom died; the fourth had a very poor outcome. In one case abnormalities on @entity353 were due to @entity3553 . We diagnosed @entity1333 in three of five @entity1 studied with MRA. We think @entity353 an important part of an MRI study in @entity1 with @entity693 . Small @entity62 due to @entity1333 can lead to tissue damage not easily recognized on routine imaging and @entity353 can be used to confirm that extra-axial collections represent empyemas.

title: Diffusion-weighted imaging in acute XXXX in infancy.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'infants']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizures']

entities_list: @entity3553 :: ('MESH:D013354', 'Disease') :: ['subdural empyemas']

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['DWI', 'diffusion weighted imaging']

entities_list: @entity4008 :: ('MESH:D016920', 'Disease') :: ['bacterial meningitis', 'Bacterial meningitis']

entities_list: @entity1333 :: ('MESH:D014657', 'Disease') :: ['septic vasculitis', 'vasculitis']

entities_list: @entity75 :: ('MESH:D001927', 'Disease') :: ['encephalopathy']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological impairment']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity693 :: ('MESH:D008581', 'Disease') :: ['meningitis']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['Multiple infarcts', 'infarcts']

entities_list: @entity62 :: ('MESH:D056784', 'Disease') :: ['cortical or deep white-matter infarcts']

answer: @entity4008 :: (MESH:D016920,Disease) :: ['bacterial meningitis']


abstract: @entity2 has @entity3082 proportions in all developed countries and many of the urban centres of the developing world. It is the most frequent @entity5 site in Singapore, accounting for 23.4% (623 cases) of all @entity5 deaths and nearly 5% of all causes in 1982. Based on incidence data for 1968-1977, among males, there was an average of about 330 cases diagnosed each year, giving an annual incidence rate of 30.7 per 100,000 and a proportion of 21% against all sites. Among females, there was an average of about 115 cases, with the incidence rate at 11.2 and the proportion 10.3% (ranking third behind breast and cervix). The risks among the Chinese were more than double those of the other ethnic groups. The Hokkien (73.2 per 100,000) and Teochew (67.0) males had one of the highest age-standardized incidence rates in the world. Most of the cases were of the @entity957 type. Among the females, the Cantonese (28.5) had about double the risks compared to the other dialect groups, and the rate was among the highest in the world. @entity420 accounted for almost 50% of the cases. The relevant host and environmental factors associated with @entity2 are discussed. Without doubt, cigarette smoking is the most important risk factor. The ultimate solution to this problem must lie in an effective smoking control programme, besides much-needed improvements in early diagnosis and treatment of the disease.

title: The epidemiology of XXXX in Singapore.

entities_list: @entity3082 :: ('MESH:D004671', 'Disease') :: ['reached epidemic']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['epidermoid carcinoma']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['Lung cancer', 'lung cancer']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['Adenocarcinomas']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung cancer']


abstract: @entity5550 ( @entity5550 ) is a proposed new diagnostic criteria in the DSM-IV, cited as an example of an @entity1277 Not Otherwise Specified (NOS). The phrase Binge Eating was introduced over 35 years ago to describe problematic behavior found in a subgroup of overweight individuals, and as a subgroup of @entity1279 . The defining characteristics of @entity5550 @entity1 are consumptions of an objectively large amount of food in discrete time periods, a lack of control during eating episodes and a lack of compensatory behavior binge. BEDs affect approximately 30% of @entity28 individuals seeking treatment. The binge eaters represent a distinct subgroup among the @entity28 with higher prevalence of comorbid @entity146 , as well as higher rates of eating pathology, as compared to normal @entity28 @entity1 . Several researches suggested that individuals use binge eating as a means of coping with emotional distress. In addition, the @entity5550 represents a distinct subgroup among @entity1279 with lower comorbid @entity146 , eating pathology and @entity146 . The present paper will review this proposed syndrome and will discuss the question of whether it is a distinct subgroup of @entity28 @entity1 or a distinct subgroup of @entity1279 @entity1 , or a new diagnostic category. This diagnostic dilemma is discussed in light of clinical and empirical literature. Clinical and therapeutic implications are presented and ideas for future research are proposed.

title: [ @entity5550 ( XXXX )--new diagnostic category].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['psychiatric disturbances', 'purging behavior']

entities_list: @entity1277 :: ('MESH:D001068', 'Disease') :: ['eating disorder']

entities_list: @entity1279 :: ('MESH:D052018', 'Disease') :: ['Bulimia Nervosa', 'bulimia nervosa']

entities_list: @entity5550 :: ('MESH:D056912', 'Disease') :: ['BED', 'binge eating disorder', 'Binge Eating Disorder']

answer: @entity5550 :: (MESH:D056912,Disease) :: ['BED']


abstract: @entity5550 ( @entity5550 ) is a proposed new diagnostic criteria in the DSM-IV, cited as an example of an @entity1277 Not Otherwise Specified (NOS). The phrase Binge Eating was introduced over 35 years ago to describe problematic behavior found in a subgroup of overweight individuals, and as a subgroup of @entity1279 . The defining characteristics of @entity5550 @entity1 are consumptions of an objectively large amount of food in discrete time periods, a lack of control during eating episodes and a lack of compensatory behavior binge. BEDs affect approximately 30% of @entity28 individuals seeking treatment. The binge eaters represent a distinct subgroup among the @entity28 with higher prevalence of comorbid @entity146 , as well as higher rates of eating pathology, as compared to normal @entity28 @entity1 . Several researches suggested that individuals use binge eating as a means of coping with emotional distress. In addition, the @entity5550 represents a distinct subgroup among @entity1279 with lower comorbid @entity146 , eating pathology and @entity146 . The present paper will review this proposed syndrome and will discuss the question of whether it is a distinct subgroup of @entity28 @entity1 or a distinct subgroup of @entity1279 @entity1 , or a new diagnostic category. This diagnostic dilemma is discussed in light of clinical and empirical literature. Clinical and therapeutic implications are presented and ideas for future research are proposed.

title: [ XXXX ( @entity5550 )--new diagnostic category].

answer: @entity5550 :: (MESH:D056912,Disease) :: ['Binge eating disorder']


abstract: @entity3362 are vasodilators of venous and arterial smooth muscle commonly prescribed both for @entity951 and @entity712 . Primarily venodilators, @entity3362 also affect the systemic circulation if administered in sufficient dosage. In the coronary circulation, the principal effect is on the large epicardial and collateral vessels. Blood is shunted toward the @entity63 subendocardium. In the majority of @entity1 with @entity951 , relief of symptoms by @entity3362 is primarily due to hemodynamic effects on preload and afterload, unless the @entity1 has @entity3361 . In @entity1 with @entity712 , @entity3362 decrease the resistance to the emptying of blood from the left ventricle as well as the filling pressure. @entity3362 are relatively well tolerated, except for an initial throbbing @entity10 which rapidly resolves as tolerance develops. @entity3362 are available in a multitude of forms including sublingual, oral, topical, transmucosal, intravenous, and spray preparations. Oral preparations undergo a first-pass effect in the liver, requiring larger doses. Other forms avoid this problem by direct transdermal absorption or the intravenous route. The latter has the advantage of rapid administration and ease of titration. The choice of @entity1507 depends upon the clinical situation.

title: @entity1507 therapy in XXXX and @entity712 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity3362 :: ('MESH:D009566', 'Chemical') :: ['Nitrates', 'nitrates']

entities_list: @entity3361 :: ('MESH:D003329', 'Disease') :: ['coronary spasm']

entities_list: @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate']

entities_list: @entity10 :: ('MESH:D006261', 'Disease') :: ['headache']

answer: @entity951 :: (MESH:D000787,Disease) :: ['angina']


abstract: @entity3362 are vasodilators of venous and arterial smooth muscle commonly prescribed both for @entity951 and @entity712 . Primarily venodilators, @entity3362 also affect the systemic circulation if administered in sufficient dosage. In the coronary circulation, the principal effect is on the large epicardial and collateral vessels. Blood is shunted toward the @entity63 subendocardium. In the majority of @entity1 with @entity951 , relief of symptoms by @entity3362 is primarily due to hemodynamic effects on preload and afterload, unless the @entity1 has @entity3361 . In @entity1 with @entity712 , @entity3362 decrease the resistance to the emptying of blood from the left ventricle as well as the filling pressure. @entity3362 are relatively well tolerated, except for an initial throbbing @entity10 which rapidly resolves as tolerance develops. @entity3362 are available in a multitude of forms including sublingual, oral, topical, transmucosal, intravenous, and spray preparations. Oral preparations undergo a first-pass effect in the liver, requiring larger doses. Other forms avoid this problem by direct transdermal absorption or the intravenous route. The latter has the advantage of rapid administration and ease of titration. The choice of @entity1507 depends upon the clinical situation.

title: XXXX therapy in @entity951 and @entity712 .

answer: @entity1507 :: (CHEBI:48107,Chemical) :: ['Nitrate']


abstract: @entity3362 are vasodilators of venous and arterial smooth muscle commonly prescribed both for @entity951 and @entity712 . Primarily venodilators, @entity3362 also affect the systemic circulation if administered in sufficient dosage. In the coronary circulation, the principal effect is on the large epicardial and collateral vessels. Blood is shunted toward the @entity63 subendocardium. In the majority of @entity1 with @entity951 , relief of symptoms by @entity3362 is primarily due to hemodynamic effects on preload and afterload, unless the @entity1 has @entity3361 . In @entity1 with @entity712 , @entity3362 decrease the resistance to the emptying of blood from the left ventricle as well as the filling pressure. @entity3362 are relatively well tolerated, except for an initial throbbing @entity10 which rapidly resolves as tolerance develops. @entity3362 are available in a multitude of forms including sublingual, oral, topical, transmucosal, intravenous, and spray preparations. Oral preparations undergo a first-pass effect in the liver, requiring larger doses. Other forms avoid this problem by direct transdermal absorption or the intravenous route. The latter has the advantage of rapid administration and ease of titration. The choice of @entity1507 depends upon the clinical situation.

title: @entity1507 therapy in @entity951 and XXXX .

answer: @entity712 :: (MESH:D006333,Disease) :: ['congestive heart failure']


abstract: OBJECTIVE: @entity29730 is an @entity3986 . It is characterized by distal muscle involvement, especially the gastrocnemius and soleus. The disease starts with @entity425 and @entity194 of the @entity291 . MATERIAL AND METHODS: Here we report on 2 @entity1 , brother and sister, from a Turkish family. Onset of the disease was at the age of 20 and 26 years of age, respectively. In both siblings, there was an early and predominant involvement of the distal muscles of the lower limbs. Creatine kinase activity was elevated 50- to 100-fold above normal values. RESULTS: Electromyography revealed a @entity121 pattern. Histology of the biceps muscles indicated some @entity121 changes consistent with @entity3986 . Occurrence in only these 2 siblings with no other family members was indicative of an autosomal recessive inheritance. CONCLUSIONS: We describe the distinctive clinical features in 2 siblings of a Turkish family with MM as differential diagnosis and histological change.

title: XXXX of the Miyoshi type.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathic']

entities_list: @entity3986 :: ('MESH:D009136', 'Disease') :: ['muscular dystrophy', 'autosomal recessive muscular dystrophy']

entities_list: @entity425 :: ('MESH:D018908', 'Disease') :: ['weakness']

entities_list: @entity29730 :: ('MESH:C537480', 'Disease') :: ['Miyoshi myopathy']

answer: @entity3986 :: (MESH:D009136,Disease) :: ['Distal muscular dystrophy']


abstract: Different antidepressant drugs are currently used for the treatment of @entity308 in @entity5 @entity1 , such as second-generation antidepressants and, recently, the extracts of Hypericum perforatum. These agents are susceptible to metabolically-based drug interactions with anticancer drugs. The aim of the present article is to provide an updated review of clinically relevant metabolic drug interactions between selected anticancer drugs and antidepressants, focusing on selective @entity750 reuptake inhibitors (SSRIs) and Hypericum extract. SSRIs can cause pharmacokinetic interactions through their in vitro ability to inhibit one or more cytochrome P450 isoenzymes (CYPs). SSRIs differ in their potential for metabolic drug interactions with anticancer drugs. @entity905 and @entity903 are potent inhibitors of @entity5320 and administration of these SSRIs reduces the clinical benefit of an anticancer drug, such as @entity440 , by decreasing the formation of active metabolites of this drug. @entity1 with @entity0 who receive @entity903 in combination with @entity440 are at increased risk for @entity204 . Other SSRIs, including @entity837 , @entity837 , are weak or negligible inhibitors of @entity5320 and are less likely to interact with anticancer drugs, while @entity3756 causes significant inhibition of this isoform only at high doses. Hypericum extract, by inducing both the @entity5322 and the @entity1262 ( @entity1262 ), can reduce the plasma concentrations of different antineoplastic agents such as @entity2213 , @entity2600 and @entity1205 , thus reducing the clinical efficacy of these drugs. Although these interactions are often predictable, the use of @entity905 , @entity903 and Hypericum extract should be avoided in @entity5 @entity1 .

title: Metabolic drug interactions between antidepressants and anticancer drugs: focus on selective XXXX reuptake inhibitors and hypericum extract.

entities_list: @entity1 :: ('9606', 'Species') :: ['Women', 'patients']

entities_list: @entity308 :: ('MESH:D003866', 'Disease') :: ['depression']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity905 :: ('MESH:D005473', 'Chemical') :: ['fluoxetine', 'Fluoxetine']

entities_list: @entity440 :: ('MESH:D013629', 'Chemical') :: ['tamoxifen']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity903 :: ('MESH:D017374', 'Chemical') :: ['paroxetine']

entities_list: @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']

entities_list: @entity3756 :: ('MESH:D020280', 'Chemical') :: ['sertraline']

entities_list: @entity837 :: ('MESH:D015283', 'Chemical') :: ['escitalopram', 'citalopram']

entities_list: @entity750 :: ('MESH:D012701', 'Chemical') :: ['serotonin']

entities_list: @entity2213 :: ('MESH:C097613', 'Chemical') :: ['imatinib']

answer: @entity750 :: (MESH:D012701,Chemical) :: ['serotonin']


abstract: In order to examine the appearance of synaptic vesicles and to correlate it with the formation of the synaptic layers, we have determined the staining pattern of a murine monoclonal antibody (SV 48) to a synaptic vesicle-associated protein in developing @entity35 retina. The antigen was detected by the indirect immunofluorescence technique using cryostat sections of @entity1604 -fixed retinas. In the adult retina, the antibody stained both the outer plexiform (OPL) and the @entity389 ( @entity389 ). The nuclear layers and the nerve fiber layer (NFL) were devoid of any staining. In prenatal and early postnatal (P) retinas, the antibody stained two bands which corresponded to the respective locations of the NFL and @entity389 . Staining in the NFL increased until P-4 and began to decline subsequently, and by @entity26752 little staining was left in this layer. In contrast, in the @entity389 , the intensity of staining increased gradually and leveled off by P-10. In the outer retina, a band of fluorescence corresponding to the OPL was first observed at @entity22545 and increased in intensity up to P-10. Immunoblotting studies showed that the major immunoreactive material from adult and embryonic retinas had a Mr approximately 65,000-67,000. As expected from its developmental pattern, all bands appeared initially in the central retina and subsequently in the peripheral retina. Our results show that the synaptic vesicle-protein is present in the nerve fiber layer before synaptogenesis in the central nervous system. Subsequently, the protein is lost from the NFL, possibly as a consequence of synapse formation.

title: Developmental expression of a synaptic vesicle-specific protein in the XXXX retina.

entities_list: @entity389 :: ('MESH:D007759', 'Disease') :: ['IPL', 'inner plexiform layers']

entities_list: @entity1604 :: ('MESH:C003043', 'Chemical') :: ['paraformaldehyde']

answer: @entity35 :: (10116,Species) :: ['rat']


abstract: The study evaluated the effects of @entity21750 use and machine enclosure on workers' exposure to bacteria, endotoxins, and @entity406 in the use of metalworking fluids (MWF). Concentrations of @entity21750 and bacterial contaminants were monitored in bulk samples of MWF from two machines in one workplace. One of the machines was used normally; @entity21750 was added to the other when needed. Air sampling was used to estimate workers' exposure to endotoxins at 18 workplaces near enclosed and open machines. Concentrations of @entity21750 in MWF and @entity406 in the air were measured. Some recirculating local exhaust ventilation systems were also tested. The endotoxin and bacteria concentrations in the biocide test of MWF rapidly increased when the biocide levels decreased below 500 ppm. Airborne concentrations of endotoxins were substantially lower near enclosed machines than near open ones. Concentrations of airborne @entity406 were below the Finnish occupational exposure limit at the existing levels of @entity21750 in MWF. Concentrations of @entity21750 in MWF correlated well with those of @entity406 in the air near the machines (correlation coefficient r=.69). The results showed that the @entity21750 levels in MWF should continuously be kept high enough (>500 ppm) to prevent workers' exposure to endotoxins and bacteria. Overdosing with @entity21750 , however, should be avoided, so that the levels of airborne @entity406 remain low. @entity21750 levels in MWF can be followed by the method described in this article. Workers' exposure to contaminants of MWF can be reduced substantially by enclosing the machines and equipping them with local exhausts.

title: Control of workers' exposure to airborne endotoxins and XXXX during the use of metalworking fluids.

entities_list: @entity21750 :: ('CHEBI:38056', 'Chemical') :: ['triazine', 'Triazine']

entities_list: @entity406 :: ('MESH:D005557', 'Chemical') :: ['formaldehyde']

answer: @entity406 :: (MESH:D005557,Chemical) :: ['formaldehyde']


abstract: SUMMARY: Effectiveness of restricted and desired gains index selection to change growth and body composition was tested in @entity19 . Replicate lines were selected within full-sib families as follows: RI, restricted index to increase 12-week body weight (BW) and @entity353 ( @entity353 ) with no change in right epididymal fat pad weight (EF); DG, desired gains index to increase BW and @entity353 and decrease EF and right subcutaneous fat pad weight (SF) in designated proportions; RS, random selection. Realized heritabilities of index units, converted to an individual basis, were 0.65    0.17 in RI and 0.50    0.23 in DG, which exceeded the respective base population estimates of 0.32    0.11 and 0.37   0.11, calculated as twice the regression of son on sire. Realized genetic correlation between the two selection index units of 0.87    0.12 was not significantly different from the base population estimate of 0.91    0.21. Realized correlated responses in component traits of the indices did not agree closely with expectation. Possible explanations for these discrepancies include genetic drift, weak selection intensity, discrepancies between estimated and true genetic parameters and changes in genetic parameters due to selection. Antagonistic selection for multiple traits may magnify the importance of these factors. ZUSAMMENFASSUNG: Restringierte und erw  nschte genetische Fortschritte zur Ver  nderung von Wachstum und K  rperzusammensetzung von M  usen Die Wirksamkeit restraingierter und erw  nschter Fortschritt-Indexselektionsver  nderung von Wachstum und K  rpergewicht wurde bei M  usen gepr  ft. Wiederholungslinien wurden innerhalb Vollgeschwisterfamilien folgenderma  en selektiert: RI, restringierter Index zur Steigerung des 12-Wochengewichtes (BW), Schlachtk  rperh  lfte ( @entity353 ) ohne   nderung des rechten Nebenhodenfettgewichts (EF); TG, erw  nschter Zuchtfortschrittindex zur Steigerung von BW und @entity353 und Verminderung von EF des rechten subkutanen Fettanteils (SF) in erw  nschten Verh  ltnissen; RS Zufallsselektion. Realisierte Heritabilit  tswerte im Index, auf individuelle Basis umgerechnet, waren 0,65   0,17 bei RI und 0,50    0,23 bei DG, die die diesbez  glichen Basispopulationssch  tzungen von 0,23   0,11 und 0,37   0,11   bertrafen. Diese wurden als die doppelte Regression von Sohn auf Vatertier berechnet. Realisierte genetische Korrelationen zwischen den zwei Selektionsindexeinheiten von 0,87 unterschieden sich nicht signifikant vom Basispopulationswert 0,91    0,21. Realisierte korrelierte Selektion-sreaktionen in den Teilmerkmalen der Indices haben mit den Erwartungswerten nicht gut   bereingestimmt. M  gliche Erkl  rung f  r diese Abweichung beinhalten genetische Drift, schwache Selektionsintensit  t, Nicht  bereinstimmung zwischen gesch  tzten und wahren genetischen Parametern und Ver  nderungen in diesen durch Selektion. Antagonistische Selektion f  r mehrere Merkmale k  nnte die Bedeutung dieser Faktoren steigern.

title: Multitrait restricted and desired gains selection indices designed to change growth and body composition in XXXX (1).

entities_list: @entity353 :: ('MESH:D015431', 'Disease') :: ['HC', 'hind carcass weight']

answer: @entity19 :: (10090,Species) :: ['mice']


abstract: SUMMARY: To identify the @entity11520 chromosome carrying the genes coding for GAPD, @entity72767 , and @entity72768 , karyotypic examination was carried out on 14 buffalo-hamster hybrid clones previously tested for presence of this syntenic group. In @entity291 , this group (U3) has been assigned to chromosome 5, which is assumed to be homologous to the long arm of buffalo chromosome 4. Chromosome 4 was present in all five clones expressing the three enzymes, and absent in all seven negative clones, indicating that in the buffalo GAPD, @entity72767 , and @entity72768 are located on chromosome 4. One clone, expressing GAPD and @entity72767 , but not @entity72768 , was found to carry a translocation between hamster marker chromosome M(2) and buffalo 4q1  >  4qter. In another clone, expressing @entity72768 , but not GAPD and @entity72767 , chromosome 4 was absent, while a very small, unidentifiable acrocentric was present. These observations suggest that @entity72768 is located in the proximal part of 4q1, and that GAPD and @entity72767 are located more distally, in 4q1  >  4q2. ZUSAMMENFASSUNG: Lokalisierung von Genen auf Chromosom 4 des Flu  b  ffels durch B  ffel-Hamster-Hybridzellen Zur Identifikation von Flu  b  ffelchromosomen mit Genen f  r GAPD, @entity72767 und @entity72768 wurden Karyotypenbestimmungen an 14 B  ffel-Hamster-Hybridklonen durchgef  hrt, die vorher auf Anwesenheit der betreffenden synthenischen Gruppen gepr  ft worden waren. Bei Rindern wird diese Gruppe (U3) dem Chromosom 5 zugeordnet, welches als homolog mit dem langen Arm des B  ffelchromosoms 4 betrachtet wird. Chromosom 4 war in allen f  nf Klonen, die die drei Enzyme exprimiert haben, vorhanden und fehlte in allen sieben negativen klonen, so da   angenommen werden kann, da   sich bei B  ffeln GAPD, @entity72767 und @entity72768 auf Chromosom 4 befinden. Bei einem Klon, der GAPD und @entity72767 , aber nicht @entity72768 zeigte, wurde eine Translokation zwischen dem Hamstermarkerchromosom M2 und B  ffel 4q1  >  4qter gefunden. Im einem anderen Klon, der @entity72768 , nicht aber GAPD und @entity72767 zeigte, war Chromosom 4 nicht vorhanden, wohl aber ein sehr kleines, nicht identifizierbares akrozen-trisches Chromosom. Diese Beobachtungen weisen darauf hin, da   sich @entity72768 im proximalen Teil von 4q1 befindet und GAPD und @entity72767 vertu distal in 4q1  >  4q2 lokalisiert sind.

title: Assignment of genes to chromosome 4 of the XXXX with a panel of buffalo-hamster hybrid cells.

answer: @entity11520 :: (89462,Species) :: ['River buffalo']


abstract: The mainstay of treatment for @entity955 , AF, remains pharmacologic control, either by maintaining sinus rhythm or by controlling the ventricular rate and allowing AF to continue. In @entity1 where pharmacologic therapy i not effective, not tolerated or contraindicated, nonpharmacologic treatment may be beneficial. In the last two decades the number of nonpharmacologic treatment options (catheter ablation, cardiac pacing, internal defibrillation, and @entity943 surgery) for AF have markedly increased and the number of @entity1 undergoing such treatment is steadily increasing. The most important reason for these treatment strategies is the hope of reducing symptoms, preventing complications and improving quality of life, QoL. However, the impact of nonpharmacologic therapy on QoL is far from established. Following a short presentation of the basic definitions and instruments used in QoL research the present paper reviews clinical studies that have assessed QoL in @entity1 undergoing nonpharmacologic treatment of AF. Major limitations and methodological problems are emphasized. Among these are highly selected often-heterogeneous @entity1 groups, small size, lack of control group and the use of non-validated QoL instruments. Furthermore, in most studies antiarrhythmic medication have been discontinued at the time of the intervention and it is not clear to which degree the improvement in QoL is related solely to the nonpharmacologic treatment or to the removal of drug related adverse effects. Although the currently available data from adequately designed studies are sparse and further investigations are needed, it is noteworthy that the majority of @entity1 undergoing nonpharmacologic treatment report enhanced QoL.

title: Quality of life in nonpharmacologic treatment of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity943 :: ('MESH:D001145', 'Disease') :: ['dysrhythmia']

entities_list: @entity955 :: ('MESH:D001281', 'Disease') :: ['atrial fibrillation']

answer: @entity955 :: (MESH:D001281,Disease) :: ['atrial fibrillation']


abstract: @entity462 proteases such as caspases play important roles in @entity204 ( @entity204 ) of metazoans. Plant metacaspases (MCPs), a family of @entity462 proteases structurally related to caspases, have been hypothesized to be ancestors of metazoan caspases, despite their different substrate specificity. @entity958 contains six type II MCP genes (AtMCP2a-f). Whether and how these individual members are involved in controlling @entity204 in plants remains largely unknown. Here we investigated the function and regulation of AtMCP2d, the predominant and constitutively expressed member of type II MCPs, in stress-inducible @entity204 . Two AtMCP2d mutants (mcp2d-1 and mcp2d-3) exhibited reduced sensitivity to @entity204 -inducing mycotoxin @entity18639 as well as oxidative stress inducers, whereas AtMCP2d over-expressors were more sensitive to these agents, and exhibited accelerated cell-death progression. We found that AtMCP2d exclusively localizes to the cytosol, and its accumulation and self-processing patterns were age-dependent in leaves. Importantly, active proteolytic processing of AtMCP2d proteins dependent on its catalytic activity was observed in mature leaves during mycotoxin-induced cell death. We also found that mcp2d-1 leaves exhibited reduced cell death in response to @entity3437 carrying avirulent gene avrRpt2, and that self-processing of AtMCP2d was also detected in wild-type leaves in response to this pathogen. Furthermore, increases in processed AtMCP2d proteins were found to correlate with conditional cell-death induction in two lesion-mimic mutants (cpr22 and ssi4) that exhibit spontaneous cell-death phenotypes. Taken together, our data strongly suggest that AtMCP2d plays a positive regulatory role in biotic and abiotic stress-induced @entity204 .

title: XXXX metacaspase 2d is a positive mediator of cell death induced during biotic and abiotic stresses.

entities_list: @entity462 :: ('MESH:D003545', 'Chemical') :: ['cysteine', 'Cysteine']

entities_list: @entity958 :: ('3702', 'Species') :: ['Arabidopsis thaliana']

entities_list: @entity18639 :: ('MESH:C056933', 'Chemical') :: ['fumonisin B1']

entities_list: @entity3437 :: ('317', 'Species') :: ['Pseudomonas syringae']

entities_list: @entity204 :: ('MESH:D003643', 'Disease') :: ['PCD', 'programmed cell death']

answer: @entity958 :: (3702,Species) :: ['Arabidopsis']